(EAY 131-E MATCH): AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
Description: 

AZD9291 is an irreversible, mutant specific EGFR tyrosine kinase inhibitor. It is effective in pre-clinical tumor models and clinical trials in patients with TKI sensitizing and T790M resistant tumors. It is generally well tolerated. Activating mutations within the epidermal growth factor receptor (EGFR) mutations are present in approximately 20% of all lung adenocarcinomas. EGFR -mutant cancers are dependent on EGFR signaling for growth and survival, making inhibition of EGFR an attractive therapeutic target.

Study Number: 

NCG 275215 E

Phase: 
2
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02465060

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.